FIS supplementation can prevent or alleviate hepatic and myocardial fibrosis by inhibiting the expression of fibrosis-related genes and inactivating TGF-β1/Smad3 signaling (Liu et al., 2019; Choi et al., 2020; Hu et al., 2020). Here, TGFB1 is linked to Myocardial fibrosis.